Overview

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This study will investigate the effects of therapeutic and supratherapeutic oral doses of CBP-307 on the QTc interval in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Suzhou Connect Biopharmaceuticals, Ltd.
Treatments:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination